ArticleScience advances2026

A high-density CRISPR activation platform for mapping cancer dependencies and resistance pathways ex vivo and in vivo.

Sarah T Diepstraten et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.